Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

The pharmaceutical giant also issued fiscal 2025 profit guidance ... said demand for its weight loss and diabetes drugs would not meet its lofty expectations. Notably, Eli Lilly said it plans ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs soared but saw lower realized prices. Demand in the U.S. has far outpaced supply ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug ...

Analysts had expected profit of $4.52 billion ... the Danish company behind weight-loss drugs Ozempic and Wegovy, topped estimates in its fourth-quarter report. Eli Lilly shares were up roughly ...

Eli Lilly reported mixed results for the fourth quarter as sales of its blockbuster weight loss and diabetes drugs ... giant also issued fiscal 2025 profit guidance of $22.05 to $23.55 per share ...

Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates ... Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound grew to $3. ...